Bristol-Myers Squibb and Infinity collaborate to test Opdivo and IPI-549 combination

Bristol-Myers Squibb Company (BMY) and Infinity Pharmaceuticals will collaborate to conduct a clinical study of Bristol-Myers Squibb ’s Opdivo in combination with Infinity’s IPI-549 to treat advanced solid tumours.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals | Study